000894652 001__ 894652
000894652 005__ 20220406202833.0
000894652 0247_ $$2doi$$a10.1093/brain/awab003
000894652 0247_ $$2ISSN$$a0006-8950
000894652 0247_ $$2ISSN$$a1460-2156
000894652 0247_ $$2Handle$$a2128/28847
000894652 0247_ $$2altmetric$$aaltmetric:106027554
000894652 0247_ $$2pmid$$apmid:34000009
000894652 0247_ $$2WOS$$aWOS:000769928100024
000894652 037__ $$aFZJ-2021-03337
000894652 082__ $$a610
000894652 1001_ $$00000-0001-9723-3043$$aWalsh, Jessica$$b0
000894652 245__ $$aMicroglial activation and blood–brain barrier permeability in cerebral small vessel disease
000894652 260__ $$aOxford$$bOxford Univ. Press$$c2021
000894652 3367_ $$2DRIVER$$aarticle
000894652 3367_ $$2DataCite$$aOutput Types/Journal article
000894652 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1635246634_32551
000894652 3367_ $$2BibTeX$$aARTICLE
000894652 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000894652 3367_ $$00$$2EndNote$$aJournal Article
000894652 520__ $$aCerebral small vessel disease (SVD) is a major cause of stroke and dementia. The underlying pathogenesis is poorly understood, but both neuroinflammation and increased blood–brain barrier permeability have been hypothesized to play a role, and preclinical studies suggest the two processes may be linked. We used PET magnetic resonance to simultaneously measure microglial activation using the translocator protein radioligand 11C-PK11195, and blood–brain barrier permeability using dynamic contrast enhanced MRI. A case control design was used with two disease groups with sporadic SVD (n = 20), monogenic SVD (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, CADASIL), and normal controls (n = 20) were studied. Hotspots of increased glial activation and blood–brain barrier permeability were identified as values greater than the 95th percentile of the distribution in controls. In sporadic SVD there was an increase in the volume of hotspots of both 11C-PK11195 binding (P = 0.003) and blood–brain barrier permeability (P = 0.007) in the normal appearing white matter, in addition to increased mean blood–brain barrier permeability (P < 0.001). In CADASIL no increase in blood–brain barrier permeability was detected; there was a non-significant trend to increased 11C-PK11195 binding (P = 0.073). Hotspots of 11C-PK11195 binding and blood–brain barrier permeability were not spatially related. A panel of 93 blood biomarkers relating to cardiovascular disease, inflammation and endothelial activation were measured in each participant; principal component analysis was performed and the first component related to blood–brain barrier permeability and microglial activation. Within the sporadic SVD group both hotspot and mean volume blood–brain barrier permeability values in the normal appearing white matter were associated with dimension 1 (β  =  0.829, P = 0.017, and β  =  0.976, P = 0.003, respectively). There was no association with 11C-PK11195 binding. No associations with blood markers were found in the CADASIL group. In conclusion, in sporadic SVD both microglial activation and increased blood–brain barrier permeability occur, but these are spatially distinct processes. No evidence of increased blood–brain barrier permeability was found in CADASIL.
000894652 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000894652 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000894652 7001_ $$0P:(DE-HGF)0$$aTozer, Dan J$$b1
000894652 7001_ $$00000-0002-1504-1767$$aSari, Hasan$$b2
000894652 7001_ $$0P:(DE-HGF)0$$aHong, Young T$$b3
000894652 7001_ $$0P:(DE-HGF)0$$aDrazyk, Anna$$b4
000894652 7001_ $$0P:(DE-HGF)0$$aWilliams, Guy$$b5
000894652 7001_ $$0P:(DE-Juel1)131794$$aShah, N Jon$$b6$$ufzj
000894652 7001_ $$0P:(DE-HGF)0$$aO’Brien, John T$$b7
000894652 7001_ $$0P:(DE-HGF)0$$aAigbirhio, Franklin I$$b8
000894652 7001_ $$0P:(DE-HGF)0$$aRosenberg, Gary$$b9
000894652 7001_ $$0P:(DE-HGF)0$$aFryer, Tim D$$b10
000894652 7001_ $$0P:(DE-HGF)0$$aMarkus, Hugh S$$b11$$eCorresponding author
000894652 773__ $$0PERI:(DE-600)1474117-9$$a10.1093/brain/awab003$$gVol. 144, no. 5, p. 1361 - 1371$$n5$$p1361 - 1371$$tBrain$$v144$$x1460-2156$$y2021
000894652 8564_ $$uhttps://juser.fz-juelich.de/record/894652/files/awab003.pdf
000894652 8564_ $$uhttps://juser.fz-juelich.de/record/894652/files/Walsh.pdf$$yPublished on 2021-05-17. Available in OpenAccess from 2022-05-17.
000894652 909CO $$ooai:juser.fz-juelich.de:894652$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000894652 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich$$b6$$kFZJ
000894652 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000894652 9141_ $$y2021
000894652 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-29
000894652 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000894652 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-29
000894652 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-29
000894652 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-29
000894652 915__ $$0StatID:(DE-HGF)0530$$2StatID$$aEmbargoed OpenAccess
000894652 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN : 2019$$d2021-01-29
000894652 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bBRAIN : 2019$$d2021-01-29
000894652 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-29
000894652 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-29
000894652 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-29
000894652 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000894652 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-29
000894652 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-29
000894652 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-29
000894652 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-29$$wger
000894652 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-29
000894652 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x0
000894652 9201_ $$0I:(DE-Juel1)INM-11-20170113$$kINM-11$$lJara-Institut Quantum Information$$x1
000894652 9201_ $$0I:(DE-Juel1)VDB1046$$kJARA-BRAIN$$lJülich-Aachen Research Alliance - Translational Brain Medicine$$x2
000894652 980__ $$ajournal
000894652 980__ $$aVDB
000894652 980__ $$aUNRESTRICTED
000894652 980__ $$aI:(DE-Juel1)INM-4-20090406
000894652 980__ $$aI:(DE-Juel1)INM-11-20170113
000894652 980__ $$aI:(DE-Juel1)VDB1046
000894652 9801_ $$aFullTexts